Jasper Therapeutics (JSPR) to Release Earnings on Tuesday

Jasper Therapeutics (NASDAQ:JSPR) will likely be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($1.17) per share for the quarter.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). On average, analysts expect Jasper Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Jasper Therapeutics Stock Up 2.0 %

Shares of NASDAQ:JSPR opened at $4.52 on Friday. The stock has a market capitalization of $67.90 million, a PE ratio of -0.95 and a beta of 2.74. The firm’s 50 day moving average price is $4.66 and its 200-day moving average price is $11.49. Jasper Therapeutics has a twelve month low of $3.13 and a twelve month high of $26.84.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JSPR. UBS Group assumed coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $38.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.